MAIA Biotechnology, Inc. disclosed a poster presenting efficacy data from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer, originally presented on March 28, 2025, at the European Lung Cancer Congress. The poster will also be available on the company's website on the same date.